AVDL - Avadel Pharmaceuticals plc
(NaN%)
Sell
Weak Growth●Stock Price Very High
34%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 82.76%
Operating Income turning Positive
Net Income is Negative but improving
Earnings Per Share (EPS) is Zero
Net Margin is -0.11%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 2.76
Debt Ratio is 0.51
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations turning Positive
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Avadel Pharmaceuticals plc (AVDL) - https://www.avadel.com/
avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.Exchange - NASDAQ
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Gregory Divis
Employees - 144
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.